Celebrating A ‘Cancerversary’ In A COVID-19 World

January 16th 2021, 8:00pm

By Kelly Irvin

It’s okay for me to not feel like celebrating my 5-year cancerversary in a world that is upside down and backward because of COVID-19. Yes, I’m grateful and blessed, but I’m not bullet-proof. I’m human. I don’t have to feel guilty. None of us do.

Alleviating Pandemic-Related Anxiety Over Returning to the Clinic for Clinical Trials

January 16th 2021, 2:00pm

In an interview with CURE®, expert Martha Raymond explains the importance of clinical trials during the COVID-19 pandemic and how clinicians must find a way to help ease patients anxieties as they return to the clinic.

Areas Patients with CLL Can Focus On to Maintain Their Health Beyond Treatment

January 15th 2021, 10:00pm

By Jessica Skarzynski

In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute discussed why it’s important for patients with CLL, regardless of their treatment plans, to keep up on vaccinations and maintain a regular cancer screening schedule.

Enhertu Receives FDA Approval for Gastroesophageal, Gastric Cancer Subset

January 15th 2021, 9:44pm

By Ryan McDonald

The Food and Drug Administration approved Enhertu to treat adults with locally advanced or metastatic HER2-positive gastroesophageal or gastric cancer who have previously received a trastuzumab-based treatment regimen.

Communication is Key When Navigating Cancer and a Marriage

January 15th 2021, 2:00pm

By Jessica Skarzynski

Janice and Rex Cowden sat down for an interview to discuss how to navigate a cancer diagnosis as a couple, and that communication is not only the key to a better cancer journey but a better marriage.

FDA Approves Xalkori for Children, Young Adults With Relapsed or Refractory Anaplastic Large Cell Lymphoma

January 14th 2021, 10:49pm

By Ryan McDonald

The Food and Drug Administration approved the supplemental new drug application for Xalkori (crizotinib) to treat children and young adults between the ages of 1 and 21 with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma.

Living in Low-Income, Rural Households Associated With Greater Risk of Death for Patients With Liver Cancer

January 14th 2021, 10:30pm

By Colleen Moretti

Patients with hepatocellular carcinoma who live in low-income and rural households are less likely to receive high quality care and therefore are more likely to be diagnosed with an advanced stage cancer.

Triple Therapy with Darzalex Improves Pain, Quality of Life in Newly Diagnosed Multiple Myeloma Ineligible for Stem Cell Transplantation

January 14th 2021, 8:00pm

By Darlene Dobkowski, MA

Quality of life improved in patients treated with Darzalex, Revlimid and dexamethasone compared with Revlimid and dexamethasone, and were present regardless of age, functional status and the depth of their treatment response.

Risky Business: Navigating COVID Challenges To Still Find Connection

January 14th 2021, 5:00pm

By Steve Rubin

A survivor discusses the challenges of finding connections during COVID-19.

Adding Copiktra to Standard of Care Chemotherapy Combination in CLL Could Improve Outcomes, But Not Without Toxicities

January 14th 2021, 3:00pm

By Jessica Skarzynski

In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute in Boston discussed how the addition of Copiktra to a three-drug chemotherapy combination improved outcomes in patients with CLL, with more than half achieving complete remission.

Novel Drug with Dexamethasone Safe in Heavily Pretreated Multiple Myeloma

January 13th 2021, 10:00pm

By Darlene Dobkowski, MA

Melflufen with dexamethasone was an effective treatment option for patients with relapsed or refractory multiple myeloma previously treated with a specific chemotherapy drug and/or an anti-CD38 monoclonal antibody.

Patients With Lung Cancer Subset Report Better Quality of Life, Improved Survival After Treatment with Lorbrena

January 13th 2021, 7:00pm

By Colleen Moretti

Patients with ALK-positive non-small-cell lung cancer who received Lorbrena reported better quality of life and had longer progression-free survival than patients who received Xalkori.

To Tell or Not to Tell About My Mastectomy

January 13th 2021, 5:00pm

By Shakay J. Kizirian , MSW, LCSW

A cancer survivor discusses how she decides to discuss her mastectomy and the acceptance of her body after treatment for cancer.

How Pharmaceutical Innovation is Saving the World From a Pandemic

January 13th 2021, 4:00pm

By Mike Hennessy Sr., Chairman

Let’s not mince words: The U.S. and the world must appreciate the role of the pharmaceutical industry — the researchers and physicians — who are rescuing the world from COVID-19.

Men with Prostate Cancer Experience Higher Levels of Fatigue Due to Inflammation

January 13th 2021, 2:00pm

By Colleen Moretti

Men who are receiving androgen deprivation therapy treatment for prostate cancer experience higher levels of fatigue and depression when compared to men who are not receiving treatment and who have no history of cancer.